SGF29

SGF29 is a chromatin reader subunit of SAGA-family transcriptional coactivator complexes that couples recognition of active histone marks to transcriptional activation across diverse biological contexts. Its tandem Tudor domains bind H3K4me2/3 through a bipartite pocket architecture, recruiting the SAGA complex to target promoters to stimulate histone H3 acetylation (H3K14ac, H3K9ac) (PMID:21685874, PMID:23894581, PMID:41843375). Beyond HAT-module recruitment, SGF29 maintains H3K4me3 levels by facilitating SET1/MLL complex association, functions as a heterochromatin boundary element through both its N-terminal and Tudor-domain regions independently of Gcn5, and forms phase-separated nuclear condensates via its intrinsically disordered region (Arg207) during senescence to concentrate transcriptional machinery at target loci such as CDKN1A (PMID:23894581, PMID:24307402, PMID:37935676). SGF29 Tudor domain–dependent chromatin reading sustains oncogene expression in AML and is required for pluripotency gene regulation through interaction with Oct4 and Nanog in embryonic stem cells (PMID:38048593, PMID:41843375).

1. 2007 Medium

   Establishing SGF29 as a bona fide SAGA-family complex subunit answered whether this uncharacterized protein was a core component of transcriptional coactivator machinery and directly linked it to c-Myc target gene activation.

   Evidence Reciprocal co-immunoprecipitation with ADA3, GCN5, and SPT3 plus ChIP at c-Myc targets in rat cells

   PMID:17334388

   Open questions at the time

   • No structural basis for SGF29 integration into the complex
   • Mechanism by which SGF29 contributes to target gene selectivity undefined
   • Only rat system examined
2. 2011 High

   Structural determination of the tandem Tudor domains revealed how SGF29 reads H3K4me2/3 through a face-to-face dual-pocket architecture, establishing the molecular mechanism by which SAGA is recruited to active chromatin.

   Evidence Crystal structures of yeast and human SGF29 Tudor domains bound to methylated histone peptides, validated by in vivo ChIP showing H3 acetylation dependence on Tudor–H3K4me binding

   PMID:21685874

   Open questions at the time

   • Full-length SGF29 structure in complex with SAGA not determined
   • Relative contributions of H3K4me2 versus H3K4me3 recognition in vivo not resolved
3. 2013 Medium

   Discovery that SGF29 loss reduces both H3K14ac and H3K4me3 at stress-responsive promoters and diminishes ASH2L occupancy revealed an unexpected dual role: SGF29 coordinates SAGA-mediated acetylation with SET1/MLL-mediated methylation maintenance.

   Evidence SGF29 knockdown with ChIP for H3K14ac, H3K4me3, and ASH2L at GRP78/CHOP promoters during ER stress

   PMID:23894581

   Open questions at the time

   • Direct physical interaction between SGF29 and SET1/MLL complex subunits not demonstrated
   • Whether the dual role is gene-specific or genome-wide is unknown
4. 2013 Medium

   Demonstration that SGF29's Tudor domain and N-terminal region independently serve as heterochromatin boundary elements—independently of Gcn5—revealed a SAGA-HAT-independent chromatin function for SGF29.

   Evidence Domain deletion analysis and genetic epistasis with Gcn5 deletion in S. cerevisiae boundary assays

   PMID:24307402

   Open questions at the time

   • Molecular mechanism of boundary formation not identified
   • Whether boundary function is conserved in mammals is untested
   • Whether H3K4me reading is required for boundary activity is unclear
5. 2023 Medium

   Finding that SGF29 forms liquid-like nuclear condensates during senescence through Arg207-dependent phase separation, and that both condensate formation and H3K4me3 binding are required for senescence gene activation, established a biomolecular condensate mechanism for SGF29-mediated transcriptional control.

   Evidence Live-cell imaging, Arg207 mutagenesis, epigenomic and transcriptomic profiling, and ChIP in senescent cells

   PMID:37935676

   Open questions at the time

   • Single-laboratory finding not yet independently replicated
   • Identity of co-condensing factors not fully defined
   • Whether phase separation contributes to SGF29 function outside senescence is unknown
6. 2024 Medium

   A CRISPR domain-focused screen identified SGF29's Tudor domain as a non-oncogenic dependency in AML, showing that Tudor-dependent chromatin reading sustains MEIS1 and other oncogene transcription across multiple AML subtypes.

   Evidence CRISPR-Cas9 screen and SGF29 deletion in multiple AML subtype models with transcriptional and leukemogenic phenotyping

   PMID:38048593

   Open questions at the time

   • Therapeutic targeting strategy for the Tudor domain not developed
   • Whether SAGA-independent SGF29 functions contribute to AML dependency is untested
7. 2026 Medium

   Demonstrating that SGF29 interacts with Oct4 and Nanog to maintain H3K9ac and chromatin accessibility at pluripotency loci established SGF29 as an epigenetic regulator of embryonic stem cell identity and early development.

   Evidence Co-IP of SGF29 with Oct4/Nanog, SGF29 KO/KD in mouse ESCs with ATAC-seq and H3K9ac/Oct4 ChIP, blastocyst development assay

   PMID:41843375

   Open questions at the time

   • Single-laboratory study not yet independently confirmed
   • Whether SGF29–Oct4/Nanog interaction is direct or mediated through SAGA is unresolved
   • Specificity of SGF29 versus other Tudor domain proteins in pluripotency is not addressed

• Key unresolved questions include the full structural context of SGF29 within the assembled SAGA complex, whether its phase-separation capacity operates in non-senescence contexts, the mechanism underlying its heterochromatin boundary function, and whether the Tudor domain can be therapeutically targeted in AML.
• No full-length cryo-EM structure of SGF29 within SAGA
• Direct versus SAGA-mediated nature of Oct4/Nanog interaction unresolved
• Boundary element mechanism molecularly undefined